TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. completed its business combination with MedTech Acquisition Corp (Nasdaq: MTAC), a blank-check company sponsored by MedTech Acquisition Partners that went public in 2021 targeting the healthcare and medical technology sector. The August 2023 8-K filing with accession number 0001104659-23-089074 reflects a key disclosure event tied to that transaction. TriSalus, focused on oncology drug delivery with its proprietary pressure-enabled regional delivery technology, emerged as a publicly traded entity following the merger with MTAC. The combined company operates in the oncology medtech space, targeting treatment of cancers of the liver and pancreas. Sign up at SpacDesk for complete filing history, deal timelines, and sponsor data on MTAC and hundreds of other SPACs.